GSK, Cytokinetics to terminate cancer drug R&D partnership

12/10/2009 | American City Business Journals

GlaxoSmithKline will transfer to Cytokinetics all rights to GSK-923295, a drug candidate for solid tumors, by the end of February after the two drugmakers agreed to terminate their eight-year research partnership. Cytokinetics said it plans to license GSK-923295 as well as SB-743921 and SB-715992, two other cancer drug candidates that GSK turned over in 2008.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health